Only IP-10 differed significantly (p<0.01) between treated and untreated participants at week 16/24, although there were also trends for levels of other analytes, including IL-7 and MIG, to be higher in untreated AHI participants than in treated subjects that did not reach statistical significance, again likely due to the small number of subjects per group.
Carefully conducted human biomonitoring studies serve several important functions, including a) evaluating time trends for levels of environmental chemicals in humans; b) evaluating the efficacy of regulatory action; c) assessing regional differences in levels of chemicals in populations; and d) establishing baselines and distributions of body burdens for populations.
In the current study, toxic levels occurred in 7% of patients utilising the recommended dose, with no factors predictive of risk other than a trend for higher levels with an elevated creatinine level.
There was no significant change in ankyrin G levels, but there was a trend for elevated levels (152 ± 22% of WT, P = 0.14, n = 4).
After stratification by hospital levels, the trends for level 1, 2, and 3 hospitals were similar.
There were no significant differences between groups in cardiac MCT1 protein levels, although there was a general trend for lower levels in diabetic hearts compared with control hearts.
Two additional tryptophan metabolites, indoxyl sulfate and indole lactate, had a trend for higher levels among individuals with higher serum albumin levels.
By contrast, creatine, the metabolite with the third highest VIP score, had a trend for higher levels among individuals with lower serum albumin levels.
Once group-age had been taken into account, there was a nonsignificant trend for higher levels of EGP in groups with higher mean levels of relatedness between opposite sex adult group members (LMM: χ (1 ) 2 = 3.02, P = 0.082, Table 6).
